28 reports of this reaction
1.6% of all METHYL SALICYLATE reports
#20 most reported adverse reaction
PULMONARY FIBROSIS is the #20 most commonly reported adverse reaction for METHYL SALICYLATE, manufactured by Mission Pharmacal Company. There are 28 FDA adverse event reports linking METHYL SALICYLATE to PULMONARY FIBROSIS. This represents approximately 1.6% of all 1,767 adverse event reports for this drug.
Patients taking METHYL SALICYLATE who experience pulmonary fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY FIBROSIS is a less commonly reported adverse event for METHYL SALICYLATE, but still significant enough to appear in the safety profile.
In addition to pulmonary fibrosis, the following adverse reactions have been reported for METHYL SALICYLATE:
The following drugs have also been linked to pulmonary fibrosis in FDA adverse event reports:
PULMONARY FIBROSIS has been reported as an adverse event in 28 FDA reports for METHYL SALICYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY FIBROSIS accounts for approximately 1.6% of all adverse event reports for METHYL SALICYLATE, making it a notable side effect.
If you experience pulmonary fibrosis while taking METHYL SALICYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.